How does AVH's PS Ratio compare to its peers?

AVH is good value based on its Price-To-Sales Ratio (5.7x) compared to the peer average (32.2x).

How does AVH's PS Ratio compare vs other companies in the AU Biotechs Industry?

AVH is good value based on its Price-To-Sales Ratio (5.7x) compared to the Australian Biotechs industry average (10x).

What is AVH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AVH is good value based on its Price-To-Sales Ratio (5.7x) compared to the estimated Fair Price-To-Sales Ratio (7.7x).

What is the Fair Price of AVH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

AVH (A$3.92) is trading below our estimate of [[fair value]] (A$19.08)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

AVITA Medical (CHIA:AVH) - Stock Price, News & Analysis

AVH Stock Overview

Operates as a regenerative medicine company in the United States and internationally. More details

AVH fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	5/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Trading at 79.5% below our estimate of its fair value

Earnings are forecast to grow 77.55% per year

Trading at good value compared to peers and industry

Risk Analysis

Shareholders have been diluted in the past year

Has less than 1 year of cash runway

AVITA Medical, Inc. Competitors

Clinuvel Pharmaceuticals

ASX:CUV

AU$669.3m

Imugene

ASX:IMU

AU$297.5m

Aroa Biosurgery

ASX:ARX

AU$219.0m

Race Oncology

ASX:RAC

AU$231.8m

Price History & Performance

Summary of all time highs, changes and price drops for AVITA Medical
Historical stock prices
Current Share Price	US$3.92
52 Week High	US$5.61
52 Week Low	US$2.34
Beta	1.54
11 Month Change	24.05%
3 Month Change	44.65%
1 Year Change	25.04%
33 Year Change	-4.62%
5 Year Change	-68.26%
Change since IPO	63.33%

Recent updates

Shareholder Returns

	AVH	AU Biotechs	AU Market
7D	2.3%	-5.0%	1.4%
1Y	25.0%	9.8%	17.7%

Return vs Industry: AVH exceeded the Australian Biotechs industry which returned 9.8% over the past year.

Return vs Market: AVH exceeded the Australian Market which returned 17.7% over the past year.

Price Volatility

Is AVH's price volatile compared to industry and market?
AVH volatility
AVH Average Weekly Movement	6.8%
Biotechs Industry Average Movement	10.0%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

Stable Share Price: AVH has not had significant price volatility in the past 3 months compared to the Australian market.

Volatility Over Time: AVH's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2020	207	Jim Corbett	www.avitamedical.com

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time.

AVITA Medical, Inc. Fundamentals Summary

How do AVITA Medical's earnings and revenue compare to its market cap?
AVH fundamental statistics
Market cap	AU$522.82m
Earnings (TTM)	-AU$88.16m
Revenue (TTM)	AU$92.34m

5.7x

P/S Ratio

-5.9x

P/E Ratio

Is AVH overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AVH income statement (TTM)
Revenue	US$60.04m
Cost of Revenue	US$8.61m
Gross Profit	US$51.43m
Other Expenses	US$108.75m
Earnings	-US$57.32m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-2.19
Gross Margin	85.66%
Net Profit Margin	-95.47%
Debt/Equity Ratio	348.0%

How did AVH perform over the long term?

See historical performance and comparison

AVH Stock Overview

Rewards

Risk Analysis

AVITA Medical, Inc. Competitors

ASX:CUV

AU$669.3m

ASX:IMU

AU$297.5m

ASX:ARX

AU$219.0m

ASX:RAC

AU$231.8m

Price History & Performance

Recent News & Updates

AVITA Medical, Inc. Provides Financial Guidance for Fourth Quarter and Full Year of 2024

AVITA Medical, Inc. to Report Q3, 2024 Results on Nov 07, 2024

AVITA Medical, Inc. Provides Financial Guidance for Third Quarter 2024 and Updates Financial Guidance for Full Year 2024

AVITA Medical, Inc. Names Robin Vandenburgh as SVP of U.S. Commercial Sales

AVITA Medical, Inc. to Report Q2, 2024 Results on Aug 08, 2024

AVITA Medical, Inc. Announces Executive Changes

Recent updates

AVITA Medical, Inc. Provides Financial Guidance for Fourth Quarter and Full Year of 2024

AVITA Medical, Inc. to Report Q3, 2024 Results on Nov 07, 2024

AVITA Medical, Inc. Provides Financial Guidance for Third Quarter 2024 and Updates Financial Guidance for Full Year 2024

AVITA Medical, Inc. Names Robin Vandenburgh as SVP of U.S. Commercial Sales

AVITA Medical, Inc. to Report Q2, 2024 Results on Aug 08, 2024

AVITA Medical, Inc. Announces Executive Changes

AVITA Medical, Inc. Announces FDA Approval of RECELL GO

AVITA Medical, Inc. Provides Earnings Guidance for the Second of 2024

AVITA Medical, Inc., Annual General Meeting, Jun 05, 2024

AVITA Medical, Inc. to Report Q3, 2024 Results on May 13, 2024

AVITA Medical, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

AVITA Medical, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Avita Medical, Inc. Provides Preliminary Revenue Guidance for Fourth Quarter and Full-Year 2023 and First Quarter and Year 2024

AVITA Medical, Inc. to Report Q3, 2023 Results on Nov 09, 2023

AVITA Medical, Inc. announced that it expects to receive $90 million in funding from OrbiMed Advisors LLC

New minor risk - Shareholder dilution

New minor risk - Profitability

AVITA Medical, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2023

Second quarter 2023 earnings released: US$0.082 loss per share (vs US$0.05 loss in 2Q 2022)

AVITA Medical, Inc. to Report Q2, 2023 Results on Aug 10, 2023

AVITA Medical, Inc. Submits FDA PMA Supplement for Recell Go

AVITA Medical, Inc. Announces FDA Approval of RECELL for Skin Repigmentation in Vitiligo Patients

AVITA Medical, Inc. Announces Appointment of David O’Toole as Chief Financial Officer

AVITA Medical Announces FDA Approval of RECELL for Treatment of Full-Thickness Skin Defects

First quarter 2023 earnings released: US$0.073 loss per share (vs US$0.076 loss in 1Q 2022)

AVITA Medical, Inc. Expects FDA Submission of Recell Go by June 30, 2023

AVITA Medical, Inc. Announces Executive Changes

Full year 2022 earnings released: US$0.21 loss per share (vs US$0.23 loss in FY 2021)

AVITA Medical, Inc. to Report Q4, 2022 Results on Feb 23, 2023

AVITA Medical, Inc. Submits FDA PMA Application for Vitiligo

AVITA Medical, Inc. Submits PMA Supplement for Soft Tissue Repair

Third quarter 2022 earnings released: US$0.045 loss per share (vs US$0.048 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.045 loss per share (vs US$0.048 loss in 3Q 2021)

AVITA Medical, Inc. Revises Financial Guidance for the Year 2022

AVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL System for Soft Tissue Repair

AVITA Medical, Inc. to Report Q3, 2022 Results on Nov 10, 2022

AVITA Medical, Inc., Annual General Meeting, Dec 12, 2022

AVITA Medical, Inc. Announces Executive Changes

AVITA Medical, Inc. Announces Chief Executive Officer Changes

AVITA Medical, Inc. Announces Positive Topline Results from A Pivotal Randomized, Controlled Trial Evaluating the Safety and Effectiveness of the RECELL® System for Repigmentation of Stable Vitiligo Lesions

RECELL Insurance Coverage Begins in Japan for Acute Burns

Second quarter 2022 earnings released: US$0.05 loss per share (vs US$0.038 loss in 2Q 2021)

AVITA Medical, Inc. Announces Topline Results from Pivotal Trial in Patients with Soft-Tissue Injuries Using the Recell System

AVITA Medical, Inc. to Report Q2, 2022 Results on Aug 11, 2022

AVITA Medical, Inc.(NasdaqCM:RCEL) dropped from Russell 2000 Growth Index

Avita Medical, Inc. Provides Guidance for Year 2022

Avita Medical, Inc. Announces Resignation of Louis Drapeau from Board of Directors

Forecast to breakeven in 2024

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

AVITA Medical, Inc. Provides Revenue Guidance for the Calendar Year 2022

AVITA (AVH) Announces RECELL Receives Japan PMDA Approval

AVITA Medical Announces FDA Approval of New RECELL® System with Improved Ease of Use

AVITA Medical, Inc. to Report First Half, 2022 Results on Feb 28, 2022

Forecast to breakeven in 2024

AVITA Medical, Inc. Establishes Proof of Concept for Gene Therapy

Forecast to breakeven in 2024

AVITA Medical, Inc. Completes Enrollment in Pivotal Trial Evaluating the RECELL® System for Repigmentation of Stable Vitiligo

First quarter 2022 earnings released: US$0.048 loss per share (vs US$0.095 loss in 1Q 2021)

Full year 2021 earnings released: US$0.23 loss per share (vs US$0.41 loss in FY 2020)